ARTICLE | Clinical News
Aradigm's Linhaliq under EMA review for lung infection
April 6, 2018 5:46 PM UTC
Aradigm Corp. (NASDAQ:ARDM) said EMA accepted for review an MAA for Linhaliq liposomal ciprofloxacin to treat non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic Pseudomonas aeruginosa lung infections.
Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm under a 2013 deal. Linhaliq is a dual-release product consisting of a liposomal-encapsulated form of ciprofloxacin, a DNA gyrase inhibitor, mixed with a solution of free ciprofloxacin for inhalation...
BCIQ Target Profiles